West Family Investments Inc. Buys Shares of 1,017 Regeneron Pharmaceuticals, Inc. $REGN

West Family Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,017 shares of the biopharmaceutical company’s stock, valued at approximately $634,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru as the first and only treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder involving abnormal bone formation in soft tissues. In the placebo-controlled OPTIMA trial, Pasatru reduced new heterotopic ossification lesions by at least 90% at 56 weeks and significantly reduced clinician-assessed flare-ups. The approval adds a potential commercial product and strengthens Regeneron’s rare-disease portfolio. Reuters FDA approval article
• Positive Sentiment: The Pasatru approval is supported by meaningful clinical efficacy in a condition with limited treatment options, potentially giving Regeneron pricing and market-entry advantages in a highly specialized market. The financial contribution may initially be limited by FOP’s very small patient population, but the regulatory milestone can improve long-term pipeline value. Pasatru approval announcement
• Neutral Sentiment: Regeneron announced upcoming investor conference presentations by management. The events could provide additional details on Pasatru’s launch, the broader pipeline and financial outlook, but the announcement itself does not change current earnings expectations. Regeneron investor conference announcement
• Positive Sentiment: Leerink Partners raised its price target for REGN to $824, signaling continued analyst support for the shares, although the target may not fully reflect the latest trading level. Leerink Partners price target article
• Negative Sentiment: Several law firms publicized securities class actions and a September 14, 2026 lead-plaintiff deadline concerning allegations that Regeneron misrepresented risks surrounding the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, creating litigation costs, reputational risk and uncertainty around the oncology pipeline. These notices largely repeat the same underlying allegations rather than represent new operational developments. Regeneron class action notice

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $840.84 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $844.92. The firm has a 50-day simple moving average of $688.35 and a 200-day simple moving average of $715.30. The company has a market capitalization of $86.57 billion, a price-to-earnings ratio of 20.78, a price-to-earnings-growth ratio of 1.38 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $12.81 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Royal Bank Of Canada increased their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Insider Buying and Selling

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock valued at $1,090,030 over the last three months. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.